Blueprint Medicines Corporation (BPMC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Blueprint Medicines Corpo... (BPMC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

102.53

-0.83 (-0.80%)

At close: Jan 14, 2025, 3:59 PM

98.00

-4.42%

Pre-market Jan 15, 2025, 04:04 AM EST

undefined% (undefined)

Bid	41.03
Market Cap	6.51B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.09
PE Ratio (ttm)	-49.06
Forward PE	n/a
Analyst	Buy

Ask	164.09
Volume	1,241,830
Avg. Volume (20D)	685,742
Open	103.94
Previous Close	103.36
Day's Range	101.90 - 105.54
52-Week Range	72.24 - 121.90
Beta	undefined

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 30, 2015

Employees 638

Stock Exchange NASDAQ

Ticker Symbol BPMC

Website https://www.blueprintmedicines.com

Analyst Forecast

According to 18 analyst ratings, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $125, which is an increase of 21.92% from the latest price.

Buy 66.67%

Hold 27.78%

Sell 5.56%

Stock Forecasts

Next Earnings Release

Blueprint Medicines Corporation is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $145.32M, reflecting a 101.95% YoY growth and earnings per share of -0.7, making a -61.54% decrease YoY.

Why Price Moved

2 days ago · Source

+18.22%

Blueprint Medicines shares are trading higher afte... Unlock content with Pro Subscription

2 months ago · Source

+7%

Blueprint Medicines shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net product revenue guidance. Needham reiterated a Buy rating on the stock.

News

23 hours ago · zacks.com

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.

1 day ago · zacks.com

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p...

17 hours ago · zacks.com

Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?

Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

2 days ago · https://thefly.com

Blueprint Medicines price target lowered by $11 at Wedbush, here's why

Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)

1 month ago · zacks.com

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion int...

2 months ago · benzinga.com

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.

2 months ago · zacks.com

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.

2 months ago · seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief E...

2 months ago · zacks.com

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.

2 months ago · zacks.com

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, B...

2 months ago · zacks.com

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 months ago · zacks.com

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable...